Lyan Gondin Hernandez, MD
Endocrinology, Diabetes & Metabolism · Davie, FLNPI 1376920959
Payments from drug & device makers
Across 304 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$982
- Lilly USA, LLC$734
- Corcept Therapeutics$571
- Amgen$551
- Insulet Corporation$536
- Sanofi-aventis U.S. LLC$481
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,572100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $982 |
| Lilly USA, LLC | 46 | $734 |
| Corcept Therapeutics | 21 | $571 |
| Amgen | 35 | $551 |
| Insulet Corporation | 20 | $536 |
| Sanofi-aventis U.S. LLC | 21 | $481 |
| Xeris Pharmaceuticals, Inc. | 14 | $367 |
| Boehringer Ingelheim | 12 | $273 |
| Novartis | 9 | $236 |
| Dexcom, Inc. | 13 | $215 |
| AbbVie | 8 | $191 |
| Cequr Corporation | 3 | $146 |
| Abbott | 7 | $145 |
| Antares Pharma, Inc. | 3 | $138 |
| Mannkind Corporation | 5 | $123 |
| Medtronic | 5 | $109 |
| Tandem Diabetes Care, Inc. | 4 | $105 |
| Amneal Pharmaceuticals LLC | 6 | $104 |
| Ascendis Pharma Endocrinology Inc | 3 | $72 |
| Recordati_rare_diseases_inc. | 3 | $71 |
| BETA Bionics, Inc. | 4 | $66 |
| AstraZeneca | 2 | $46 |
| Gilead | 1 | $34 |
| Chiesi USA, Inc. | 1 | $33 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Verity Pharmaceuticals Inc. | 1 | $27 |
| Alvogen Inc | 1 | $27 |
| GSK | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| Halozyme Inc | 1 | $24 |
| Radius Health, Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $23 |
| Intuity Medical Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$127
How this compares
$6,584 in reported general payments places this provider in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 214 | $261,083 |
| MounjaroTirzepatide | 113 | $122,668 |
| RybelsusSemaglutide | 42 | $58,994 |
| JardianceEmpagliflozin | 43 | $49,623 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $48,393 |
| JanuviaSitagliptin Phosphate | 42 | $47,614 |
| FarxigaDapagliflozin Propanediol | 42 | $42,051 |
| TradjentaLinagliptin | 32 | $40,598 |
| TrulicityDulaglutide | 27 | $39,949 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $25,751 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $23,969 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $20,764 |
| Novolog FlexpenInsulin Aspart | 57 | $18,387 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $15,915 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $13,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $982 | $324,857269 claims |
| Lilly USA, LLCMounjaro, Trulicity | $734 | $162,617140 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $273 | $114,19093 claims |
| AstraZenecaFarxiga | $46 | $42,05142 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $481 | $20,76416 claims |
| AbbVieSynthroid | $191 | $5,02052 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $104 | $3,096136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Davie
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.